Abstract
Purpose :
To investigate the factors predictive of visual outcome and retreatment 72 months after the initial photodynamic therapy (PDT) combined with intravitreal ranibizumab (IVR) in eyes with treatment-naïve polypoidal choroidal vasculopathy (PCV).
Methods :
We retrospectively reviewed the medical records of 46 eyes from 45 patients with PCV, who were followed-up for 72 months after undergoing combination therapy. Retreatment, including combination therapy, IVR, or intravitreal aflibercept injection (IVA) alone, was administered if residual or recurrent exudative changes were present.
Results :
Mean best-corrected visual acuity (BCVA) at 72 months significantly improved from baseline (P=0.04). Spearman’s correlation coefficients analysis revealed that older age (P=3.3×10-3), male gender (P=1.0×10-4) and poor baseline BCVA (P=2.0×10-4) were associated with poor visual outcome. During the follow-up period, 37 eyes (80.4%) underwent retreatment. Median retreatment-free period was 21 months.
Conclusions :
About 80% of eyes with PCV require retreatment within 6 years after combination therapy with PDT and IVR. Visual outcome is associated with age, gender and baseline BCVA.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.